View all news
May, 07, 2020

Guardant Health Reports First Quarter 2020 Financial Results

Q1 2020 Revenue Increase of 84% Over Prior Year Period

REDWOOD CITY, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020.

Recent Highlights

  • Revenue of $67.5 million for the first quarter of 2020, representing an 84% increase over the corresponding period of 2019
  • Reported 15,257 tests to clinical customers and 5,266 tests to biopharmaceutical customers in the first quarter of 2020, representing increases of 60% and 40%, respectively, over the first quarter of 2019
  • Onboarded more than 100 clinical sites for ECLIPSE trial and expanded the target number by 50% to 150 clinical sites
  • Data published in Nature Cancer demonstrated robust concordance of Guardant360 liquid biopsy with tissue biopsy testing and builds upon the strong clinical evidence from plasmaMATCH for Guardant360’s use in metastatic breast cancer
  • Strengthened leadership team with the addition of John Saia as Senior Vice President and General Counsel

“During these challenging times, I have even more confidence in the value that liquid biopsy can bring to the cancer treatment paradigm. Cancer treatment is not something that can be delayed for long and we remain unwavering in our commitment to serving patients in the advanced cancer setting,” said Helmy Eltoukhy, PhD, co-founder and CEO. “We are operationally, financially, and strategically prepared to navigate through this difficult period and remain focused on the long-term opportunities ahead of us to transform cancer patient care.”

“Consistent with our overall belief that earlier detection leads to better outcomes, we are confident that active surveillance testing of COVID-19 would benefit many essential businesses across the country. Given the significant testing gap that currently exists, we are exploring the feasibility of developing our own high throughput diagnostic test for COVID-19 to contribute to this need,” continued Dr. Eltoukhy.

First Quarter 2020 Financial Results

Revenue was $67.5 million for the three months ended March 31, 2020, an 84% increase from $36.7 million for the three months ended March 31, 2019. Precision oncology revenue grew 109% driven by increases in testing volume and average selling price. There were 15,257 clinical tests and 5,266 biopharmaceutical tests performed during the first quarter of 2020. Development services revenue decreased 7% primarily related to the timing of achieving project related milestones for companion diagnostic development programs.

Gross profit, or total revenue less cost of precision oncology testing and cost of development services, was $47.0 million for the first quarter of 2020, an increase of $23.9 million from $23.1 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 69.6%, as compared to 63.1% for the corresponding prior year period.

Operating expenses were $81.9 million for the first quarter of 2020, as compared to $46.8 million for the corresponding prior year period, an increase of 75.1%.

Net loss attributable to Guardant Health, Inc. common stockholders was $27.7 million for the first quarter of 2020, as compared to $26.1 million for the corresponding prior year period. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.29 for the first quarter of 2020, as compared to $0.30 for the corresponding prior year period.

Cash, cash equivalents and marketable securities were $758.3 million as of March 31, 2020.

Withdrawal of 2020 Financial Guidance

Given the rapidly changing nature of the COVID-19 pandemic, the ongoing uncertainty it has caused for us, our customers and our community, as well the difficulty in predicting the pandemic’s overall impact on its future financial results, Guardant Health is withdrawing its previously announced annual revenue and net loss guidance for 2020, which was provided on February 24, 2020.

Webcast and Conference Call Information

Guardant Health will host a conference call to discuss the first quarter 2020 financial results after market close on Thursday, May 7, 2020 at 2:00 PM Pacific Time / 5:00 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com. The webcast will be archived and available for replay for at least 90 days after the event. 

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients. These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding Guardant Health’s assessment of the COVID-19 pandemic, any COVID-19 testing gap, and its preparedness for the pandemic, statements regarding the feasibility for Guardant Health to develop a high throughput diagnostic test for COVID-19, statements about the number of clinical sites targeted for Guardant Health’s ECLIPSE trial, and statements regarding the onboarding of a new General Counsel into Guardant Health’s management, which involve risks and uncertainties that could cause Guardant Health’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2019 and in its other reports filed with the Securities and Exchange Commission, including, when filed, its Quarterly Report on Form 10-Q for the period ended March 31, 2020. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health.

Investor Contact:
Carrie Mendivil
investors@guardanthealth.com

Media Contact:
Anna Czene
press@guardanthealth.com

Guardant Health, Inc.

Condensed Consolidated Statements of Operations (unaudited)
(in thousands, except per share data)

  Three Months Ended
March 31,
  2020   2019
       
Revenue:      
Precision oncology testing $ 60,246     $ 28,837  
Development services 7,264     7,818  
Total revenue 67,510     36,655  
Costs and operating expenses:      
Cost of precision oncology testing (1) 18,191     11,023  
Cost of development services 2,315     2,512  
Research and development expense (1) 37,016     16,316  
Sales and marketing expense (1) 25,115     17,807  
General and administrative expense (1) 19,785     12,661  
Total costs and operating expenses 102,422     60,319  
Loss from operations (34,912 )   (23,664 )
Interest income 3,318     2,485  
Interest expense (12 )   (293 )
Other (expense) income, net (209 )   147  
Loss before provision for income taxes (31,815 )   (21,325 )
Provision for income taxes 14     26  
Net loss (31,829 )   (21,351 )
Adjustment of redeemable noncontrolling interest 4,100     (4,700 )
Net loss attributable to Guardant Health, Inc. common stockholders $ (27,729 )   $ (26,051 )
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted $ (0.29 )   $ (0.30 )
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted 94,382     85,935  

 

(1) Amounts include stock-based compensation expense as follows:

  Three Months Ended
March 31,
  2020   2019
       
       
Cost of precision oncology testing $ 303     $ 170  
Research and development expense   2,364       1,210  
Sales and marketing expense   1,798       826  
General and administrative expense   1,873       976  
Total costs and operating expenses $ 6,338     $ 3,182  


Guardant Health, Inc.
Condensed Consolidated Balance Sheets (unaudited)
(in thousands, except share and per share data)

  March 31,
2020
  December 31,
2019
ASSETS      
Current assets:      
Cash and cash equivalents $ 152,239     $ 143,228  
Short-term marketable securities 367,853     379,574  
Accounts receivable, net 48,015     47,986  
Inventory 25,148     15,181  
Prepaid expenses and other current assets 14,137     11,389  
Total current assets 607,392     597,358  
Long-term marketable securities 238,206     268,783  
Property and equipment, net 46,685     43,668  
Right-of-use assets 30,132     29,140  
Intangible assets, net 17,681     8,524  
Goodwill 3,290     3,290  
Capitalized license fees 60     6,890  
Other assets 4,721     4,882  
Total Assets $ 948,167     $ 962,535  
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY      
Current liabilities:      
Accounts payable $ 24,378     $ 16,197  
Accrued compensation 22,935     18,557  
Accrued expenses 23,073     25,703  
Deferred revenue 11,936     12,277  
Total current liabilities 82,322     72,734  
Long-term operating lease liabilities 33,773     33,256  
Obligation related to royalty.     6,880  
Other long-term liabilities. 1,459     1,672  
Total Liabilities 117,554     114,542  
       
Redeemable noncontrolling interest. 45,500     49,600  
Stockholders’ equity:      
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 94,509,011 and 94,261,414 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively. 1     1  
Additional paid-in capital. 1,157,945     1,150,090  
Accumulated other comprehensive gain. 7,705     1,111  
Accumulated deficit (380,538 )   (352,809 )
Total Stockholders’ Equity 785,113     798,393  
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity $ 948,167     $ 962,535  

GHLogo2018F.png

 

Source: Guardant Health, Inc.

Multimedia Files:

Categories: Press Releases
View all news